Full Text View
Tabular View
No Study Results Posted
Related Studies
Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
This study has been completed.
Study NCT00590824   Information provided by University of Wisconsin, Madison

First Received on December 19, 2007.   Last Updated on October 15, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
hu14.18-IL2
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Interleukin-2
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Antineoplastic Agents
Central Nervous System Agents
Immunologic Factors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
University of Wisconsin, Madison
National Cancer Institute (NCI)
EMD Serono


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services